Office Depot (ODP), Staples (SPLS) Downside-Reaction on Judge’s Ruling; CTI BioPharma (CTIC) Green-Territory Results


Shares of Office Depot, Inc. (Nasdaq:ODP) slumped more than 20% to touch a new 52-week low in the extended session Tuesday after U.S. District Court Judge Emmet Sullivan granted a Federal Trade Commission’s injunction to block the company’s $6.3 billion merger-deal with office supplies retailer Staples, Inc. (Nasdaq:SPLS) – whose shares also plunged over 10% following the Judge’s decision -, saying it would create an unrivaled giant.

ODP stock finished the regular session at $6.09, down $0.17 (2.72%) with a total volume of 13,494,087 shares traded during the day

Office Depot, which supplies office products and services, has 550.11M Shares Outstanding. At close on Tuesday, the company had Market Capitalization of $3.35B and ODP stock one-year range was from $4.83 to $9.39 per share



CTI BioPharma Corp. (Nasdaq:CTIC) shares climbed more than 10% in after-hours trading Tuesday as the company delivered in its first quarter 2016 financial results a net income of $3.3 million, or $0.01 per share versus a net loss of ($28.6) million, or ($0.16) per share in the same period the prior year

The biopharmaceutical company disclosed in a regulatory filing ( FORM 10-Q ) that it is in the process of providing documents in response to an SEC subpoena received in January this year

CTIC stock closed at $0.43, down $0.004 (or -1.00%)

CTI BioPharma, which engages in the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers, has 280.35M Shares Outstanding, Market Capitalization (intraday) of $122.12M and CTIC stock 52-week range is between $0.25 and $2.46 per share


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at